Grail's Galleri Cancer Blood Test Faces Coverage Hurdle at Medicare
Grail's Galleri test screens for 50 cancers from a single blood draw, but broad insurance coverage depends on FDA approval after a key study fell short.
A blood test that can screen for up to 50 types of cancer simultaneously sits at the center of a coverage debate that could determine whether millions of Americans gain routine access to next-generation cancer detection. Grail's Galleri test, which works from a standard blood draw, has generated significant clinical interest, but its path to widespread reimbursement remains uncertain.
The central obstacle is FDA approval. Whether Medicare and other major health insurers will agree to cover the Galleri test hinges largely on whether the agency clears it — a regulatory milestone that has not yet been achieved. Without that clearance, coverage decisions remain in limbo, limiting the test's availability to patients who can pay out of pocket.
Read more Trump-Xi Summit: Key Issues and What May Be Left Out →
Complicating the regulatory picture is the outcome of a significant clinical study that failed to demonstrate the test's ability to reliably detect later-stage cancers. That finding is notable because one of the core promises of multi-cancer early detection tests is catching malignancies at stages when treatment is most effective. A shortfall in detecting advanced-stage disease raises questions that regulators and insurers are likely to weigh carefully.
The stakes are considerable for both patients and the broader diagnostics industry. Multi-cancer early detection is widely seen as a potential turning point in oncology, and Galleri is among the furthest along in development. A favorable FDA decision could open the door to routine screening for diseases that currently have no standard blood-based detection method, while a rejection or prolonged delay would set back the category significantly.
Continue reading at MarketWatch.com
